However, there is limited direct evidence to assess the benefits of SGLT-2Is on PH and liver fibrosis in liver cirrhosis, although several clinical trials are ongoing to explore this potential application of SGLT2-Is [30,31]. The gene discussed is SLC5A2; the disease is cirrhosis of liver.